Literature DB >> 27262728

Ocriplasmin - variable efficacy?

David H W Steel1,2, David Wong3.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27262728     DOI： 10.1007/s00417-016-3404-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  7 in total

1.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

2.  Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.

Authors:  Amal M Elbendary; Mohamed M Elwan; Hanan A Azzam; Doaa R Eldeeb
Journal:  Curr Eye Res       Date:  2011-06       Impact factor: 2.424

3.  Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography.

Authors:  D H W Steel; C Parkes; V T Papastavrou; P J Avery; I A El-Ghrably; M S Habib; M T Sandinha; J Smith; K P Stannard; D Vaideanu-Collins; R J Hillier
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

Review 4.  Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.

Authors:  Elaine de Paula Fiod Costa; Eduardo B Rodrigues; Michel E Farah; Jerry Sebag; Carsten H Meyer
Journal:  Curr Pharm Biotechnol       Date:  2011-03-01       Impact factor: 2.837

5.  Pharmacokinetics of ocriplasmin in vitreous.

Authors:  Marc D de Smet; Bart Jonckx; Marc Vanhove; Joachim van Calster; Peter Stalmans; Jean Marie Stassen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-12-13       Impact factor: 4.799

Review 6.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

7.  Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.

Authors:  Julia A Haller; Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Stephen J Pakola; Aniz Girach; Anselm Kampik; Glenn J Jaffe; Cynthia A Toth
Journal:  Ophthalmology       Date:  2014-09-18       Impact factor: 12.079
  7 in total
  2 in total

1.  It's a gas! Pneumatic release of VMT.

Authors:  T L Jackson; D H Steel
Journal:  Eye (Lond)       Date:  2016-11-04       Impact factor: 3.775

2.  OCRIPLASMIN FOR VITREOMACULAR TRACTION IN CLINICAL PRACTICE: The INJECT Study.

Authors:  David H W Steel; Niall Patton; Theodor Stappler; Niral Karia; Hans Hoerauf; Nishal Patel; Joachim Wachtlin; Thomas Raber; Petra Kozma-Wiebe
Journal:  Retina       Date:  2021-02-01       Impact factor: 3.975
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.